Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth

International Journal of Pharmaceutics

Volumn 409, Issue 1-2, 2011, Pages 260-268

  Ghosh, Indrajit ^a   Bose, Sonali ^a   Vippagunta, Radha ^a   Harmon, Ferris ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Nanomilling; Nanosuspension; Poorly soluble compound; Rod shape crystals; Vitamin E TPGS

Indexed keywords

DODECYL SULFATE SODIUM; HYDROXYPROPYLMETHYLCELLULOSE; NANOPARTICLE; NVS 102; POLOXAMER; STABILIZING AGENT; TOCOFERSOLAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; MALE; MODEL; NANOFABRICATION; NANOMILLING; NANOSUSPENSION; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROMETRY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SPECTROMETRY; SUSPENSION; VISCOSITY;

ANIMALS; BENZODIAZEPINONES; BIOLOGICAL AVAILABILITY; CRYSTALLIZATION; DOGS; DRUG CARRIERS; DRUG STABILITY; EXCIPIENTS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MALE; METHYLCELLULOSE; NANOPARTICLES; PARTICLE SIZE; PHENYLUREA COMPOUNDS; POLYETHYLENE GLYCOLS; SOLUBILITY; SUSPENSIONS; VITAMIN E;

EID: 79955033728     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.02.051     Document Type: Article

References (12)

1. J.-Y. Choi, H. Park Chul, and J. Lee Effect of polymer molecular weight on nanocomminution of poorly soluble drug Drug Deliv. 15 2008 347 353
2. A. Dolenc, J. Kristl, S. Baumgartner, and O. Planinsek Advantages of celecoxib nanosuspension formulation and transformation into tablets Int. J. Pharm. 376 2009 204 212
3. W.-G. Dai, C. Dong Liang, S. Li, and Z. Deng Combination of Pluronic/Vitamin E TPGS as a potential inhibitor of drug precipitation Int. J. Pharm. 355 2008 31 37
4. B. Frantzen Christer, L. Ingebrigtsen, M. Skar, and B. Martin Assessing the accuracy of routine photon correlation spectroscopy analy-sis of heterogeneous size distributions AAPS PharmSciTech 4 2003 Article 36
5. F. Kesisoglou, P. Santipharp, and W.Y. Nanosizing Oral formulation development and biopharmaceutical evaluation Adv. Drug Deliv. Rev. 59 2007 631 644 (Pubitemid 47285408)
6. J. Lee, J.Y. Choi, and C.H. Park Characteristics of polymers enabling nano-comminution of water-insoluble drugs Int. J. Pharm. 355 2008 328 336
7. L. Lindfors, P. Skantze, U. Skantze, M. Rasmusson, A. Zackrisson, and U. Olsson Amorphous drug nanosuspensions. 1. Inhibition of ostwald ripening Langmuir 22 2006 906 910 (Pubitemid 43282149)
8. M. Rajebahadur, H. Zia, A. Nues, and C. Lee Mechanistic study of solubility enhancement of nifedipine using vitamin E TPGS or solutol HS-15 Drug Deliv. 13 2006 201 206
9. B. Van Eerdenburgh, G. Van den Mooter, and P. Augustijns Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products Int. J. Pharm. 364 2008 64 75
10. B. Van Eerdenbrugh, J. Vermant, J.A. Martens, L. Froyen, J. Van Humbeeck, P. Augustijns, and G. Van den Mooter A screening study of surface stabilization during the production of drug nanocrystals J. Pharm. Sci. 98 2009 2091 2103
11. M.V.S. Varma, and R. Panchagnula Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo Eur. J. Pharm. Sci. 25 2005 445 453 (Pubitemid 40853872)
12. S. Verma, D. Huey Bryan, and J. Burgess Diane Scanning probe microscopy method for nanosuspension stabilizer selection Langmuir 25 2009 12481 12487